Mehta Api is an API manufacturer based in India. It holds 8 active US drug master files and 2 valid CEPs across a filed portfolio of 10 molecules. Its GMP standing is certified by EMA. Customs aggregates show $5.1M of exports covering 120 molecules to 28 destinations in 2025.
| Site | FDA FEI |
|---|---|
| Boisar, India | Not on file |
| Boisar, India | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Agomelatine | US FDA | 1 |
| Bisoprolol | EDQM | 1 |
| Cariprazine | US FDA | 1 |
| Cinacalcet | US FDA | 1 |
| Droperidol | US FDA | 1 |
| Esmolol | US FDA | 1 |
| Landiolol | US FDA | 1 |
| Mirabegron | US FDA | 1 |
| Rivaroxaban | EDQM | 1 |
| Vismodegib | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| CDSCO (India) | 1 | None |
| EMA | None | 2 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $453K | 13 |
| 2025 | Not reported | $5.1M | 28 |
| 2024 | Not reported | $3.0M | 23 |
| 2023 | Not reported | $4.1M | 32 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. Mehta Api comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.